XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues:        
Total revenue $ 189.4 $ 93.2 $ 362.5 $ 257.2
Costs and expenses:        
Research and development expense 19.5 17.4 42.6 37.1
Selling, general, and administrative expense 134.8 107.4 280.3 240.3
Change in the fair value of contingent consideration 0.4 0.0 1.3 (3.4)
Goodwill and long-lived asset impairment charges 1.8 0.0 1.8 98.4
Total costs and expenses 210.2 161.5 430.0 459.2
Operating loss (20.8) (68.3) (67.5) (202.0)
Other income (expense):        
Interest income 0.2 0.5 0.4 1.3
Interest expense (2.0) (3.1) (5.0) (5.4)
Other 18.8 12.4 18.7 16.5
Total other income, net 17.0 9.8 14.1 12.4
Loss before income tax (3.8) (58.5) (53.4) (189.6)
Income tax expense (benefit) 0.9 (3.0) (9.2) (18.9)
Net loss (4.7) (55.5) (44.2) (170.7)
Net loss attributable to non-controlling interest 0.0 (0.1) 0.0 (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (55.4) $ (44.2) $ (170.6)
Net loss per share:        
Basic (in dollars per share) $ (0.06) $ (0.74) $ (0.58) $ (2.29)
Diluted (in dollars per share) $ (0.06) $ (0.74) $ (0.58) $ (2.29)
Weighted average shares outstanding:        
Basic (shares) 77.2 74.6 76.6 74.6
Diluted (shares) 77.2 74.6 76.6 74.6
Molecular diagnostic testing        
Revenues:        
Total revenue $ 178.7 $ 83.3 $ 338.3 $ 233.8
Costs and expenses:        
Cost of revenue 48.0 32.2 92.1 75.3
Pharmaceutical and clinical services        
Revenues:        
Total revenue 10.7 9.9 24.2 23.4
Costs and expenses:        
Cost of revenue $ 5.7 $ 4.5 $ 11.9 $ 11.5